Power System Technology
ISSN:1000-3673

Received: 16-07-2025 Revised: 05-08-2025 Accepted: 02-09-2025

HIV/AIDS Infection: Transmission, Prevention, and Treatment

Faris Abdulkhaliq Alsulami

Mohammed Mashuf Almurayyi

Abdulaziz Mohammed Alshehri

Mohammed Khalefi Basbren

Affiliate to King Abdulaziz University Dental Hospital, Armed Forces hospital - Jazan

Introduction

Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) represent one of the most significant global health challenges of the modern era, fundamentally transforming our understanding of infectious disease management and infection control practices. HIV has been infecting more than 84 million people around the globe since its discovery in the early 1980s and has claimed around 36 million human lives, as well as is still affecting millions each year. This detailed analysis of the multidimensional approach to the containment of HIV/AIDS infection includes the intricate mechanism of viral infection spread, different forms of its spread, effective preventive measures, diagnostic techniques, and treatment. Making a disease that was universally fatal to its patients a chronic one that can be controlled is one of the greatest achievements in medicine by means of intense scientific research, new treatment development, and ubiquitous efforts in public health programs. The transmission of HIV, the development of effective prevention plans, the correct diagnostic testing, and the optimal treatment options are the main elements of thorough infection control.

HIV/AIDS Pathophysiology and Disease Progression

Human Immunodeficiency Virus has a complex mechanism of immune system destruction that essentially makes it unique among the other infectious agents. HIV infects CD4+ T-helper cells in particular, which are an important orchestrator of the adaptive immune response. When the virus infects a cell, it attaches to the CD4 receptors and co-receptors (mainly CCR5 or CXCR4) on the target cell, enabling viral penetration and then integration into the host cell genome via reverse transcription. This process builds-up an irreversible reservoir of viral genetic material, which is not removable by existing therapeutic interventions. Virus takes control of cellular processes to form new viral particles, which ultimately lyses the infected cells and gradually reduces the CD4+ T-cells (Kaplan et al., 2009). This organized obliteration of immune activity initiates a series of immunological breakdowns that leave the subjects more vulnerable to

Power System Technology
ISSN:1000-3673
Received: 16-07-2025 Revised: 05-08-2025 Accepted: 02-09-2025

opportunistic infections and malignancies that immunocompromised people are generally not susceptible to.

The difference between HIV infection and AIDS diagnosis is based on the progressive course of immune system weakening and severity of clinical manifestation. HIV infection is the first phase, during which people can be infected without symptoms over a few years with fairly stable immune levels, but viruses can still replicate and can be transmitted. Diagnosis AIDS is diagnosed by the presence of a CD4+ cell count of less than 200 cells per microliter (normal range 500-1500 cells/Ul) or presence of specific opportunistic infections or malignancies, independent of CD4 count. Viral load, a measurement of the number of HIV RNA copies in each milliliter of plasma, is an important measure of disease progression and treatment efficacy (McLean et al., 2024). The natural course of untreated HIV infection is divided into several stages: acute infection with large viral loads and flulike symptoms, clinical latency and progressive weakening of the immune system, and the development of AIDS with severe immunocompromise. Knowledge of this natural history is essential to focus on the urgent need to diagnose the disease at the earliest stage and begin treatment to avoid irreparable immune destruction and mitigate the risks of transmitting the disease to others.

HIV Transmission Routes and Risk Factors

Sexual transmission represents the predominant route of HIV infection globally, accounting for approximately 80% of new infections worldwide. The virus can be found in genital secretions, such as semen, vaginal, and rectal secretions, and is transmitted by direct contact with the mucous membrane during sexual intercourse. The greatest degree of transmission risk is associated with anal intercourse because rectal tissues are fragile, and virus concentrations are more pronounced in rectal secretion. The moderate risk level of vaginal intercourse is higher than the male to female position because of a higher volume of vaginal mucosa and because of a longer period of exposure to infected semen (Masur et al., 2014). Oral sexual contact is of lower risk but not negligible, especially due to the weakening of oral tissues by ulcers, cuts and inflammation. Other factors with a strong impact on the likelihood of sexual transmission include the level of viral load (increased loads pose extremely high risk of transmission), co-occurring other sexually transmitted infections (STIs, especially those that cause genital ulceration), circumcision status (uncircumcised persons are at an especially high risk of infection), and the time of the infection (acute infections are associated with extremely high risk of transmission because of high viral loads).

Blood-borne transmission encompasses several distinct exposure routes that bypass natural mucosal barriers, resulting in highly efficient viral transmission. Share of contaminated needles

Power System Technology
ISSN:1000-3673
Received: 16-07-2025 Revised: 05-08-2025 Accepted: 02-09-2025

can be considered one of the key routes of transmission in a number of areas, sharing of any injection equipment (needles, syringes, cookers, cotton filters) can transmit the infection. Exposures related to health care, although uncommon in developed nations where strict screening guidelines are in place, in the past involved blood products that were contaminated, organ transplants, and injuries related to the occupational use of needles. Transmission can be mother-to-child through pregnancy, labor and birth, or breastfeeding, where transmission rates are between 15-45% in the absence of intervention but less than 2% with comprehensive prevention planning such as antiretroviral therapy, cesarean delivery where necessary, and formula feeding. The main risk of occupation exposure is the percutaneous injury with HIV-infected sharp objects affecting healthcare workers, and the risk of transmission has been estimated at about 0.3% per exposure.

Prevention Strategies and Pre-Exposure Prophylaxis (PrEP)

Comprehensive HIV prevention plans use an integrated approach that includes behavioral, biomedical, and structural prevention to mitigate the risk of transmission among a wide range of population groups and environments. Consistent and proper condom use is an example of barrier protection techniques that, despite not being new, have demonstrated significant effectiveness in the prevention of sexual transmission with a risk reduction of about 80-95% when done consistently. Individual strategies to ensure safe injection include the availability of sterile injection materials, supervised injection rooms, opioid substitution therapy, and multifaceted harm reduction services that fully address the factors that comprise the social determinants of injection drug use. Behavioral interventions include comprehensive sexual education, risk reduction counseling, partner notification and testing program and high-risk population specific prevention education. These measures need to be culturally relevant, stigma-free, and accessible to be as effective as possible and reach vulnerable groups that might be experiencing barriers to traditional prevention services.

Pre-exposure prophylaxis (PrEP) is a novel biomedical prophylactic approach in which HIV-negative persons take antiretroviral drugs to prevent infection prior to possible exposure. The use of tenofovir disoproxil fumarate in combination with emtricitabine (TDF/FTC) in a daily dose has proven to be incredibly effective in preventing sexual transmission in cases where adherence to the drug is achieved at optimal levels. Clinical trials have revealed PrEP efficacy of between 44% to more than 90% with maximum efficacy rates directly proportional to the levels of medication adherence (Workowski, 2015). The prEP candidacy also encompasses those at significant persistent risk of HIV, such as men that have sex with men, heterosexual individuals with HIV-positive partners, and injection drug users, among others with known high-risk behavior. PEP offers time-sensitive treatment after possible HIV exposure: a 28-day antiretroviral treatment

Power System Technology
ISSN:1000-3673
Received: 16-07-2025 Revised: 05-08-2025 Accepted: 02-09-2025

course that should be started within hours but no later than 72 hours after exposure. PEP should be used in job exposures, sexual exposures, or other high-risk exposures, and its effectiveness reduces rapidly over time since it is of paramount importance to initiate medical care and treatment immediately.

HIV Testing and Diagnostic Methods

Modern testing of HIV utilizes a wide variety of methodologies intended to detect a variety of markers of infection with a balance of sensitivity, specificity, cost-effectiveness, and accessibility in mind. Rapid HIV tests give results on oral fluid, fingerstick blood, or venous blood samples in 15-20 minutes and provide immediate initial results to support same-day testing and linkage to care. These are very sensitive tests used to detect HIV antibodies but confirmatory tests are needed in case of a reactive result. ELISA assays are a classic type of laboratory based screening assay with good sensitivity and specificity to detect HIV antibodies, often taking several days to get results but a reliable screening method in a clinical and population health context (Landovitz et al., 2023). Fourth generation combination tests simultaneously identify HIV antibodies as well as p24 antigen, helping to reduce the window period and identify acute infection sooner. Polymerase chain reaction (PCR) tests have a direct association with HIV genetic material, which is the perfect method of giving a definite diagnosis and quantity of HIV virus that is used in treatment monitoring and determining acute infection.

The window period or the time interval between initial infection and when the test is detectable varies greatly among different testing methods and plays a key role in the testing strategy and interpretation of results. Antibody-only testing can take 3-12 weeks to give a reliable result, whereas combination antibody/antigen tests can detect infection in 2-6 weeks, and PCR tests can detect infection in 1-3 weeks. The latest testing guidelines include screening of all adults and adolescents (13-64 years old) at least once, screening of persons at higher risk at least once annually, and screening persons at very high risk more than once annually (Macchione et al., 2021). Specific testing methods are employed in the populations with high HIV prevalence such as men who have sex with men, injecting drug users, men and women with multiple sexual partners, and in persons with potential indicators of acute HIV infection.

Antiretroviral Therapy (ART) and Treatment Regimens

Contemporary HIV treatment protocols have revolutionized infection management, transforming HIV from a uniformly fatal condition to a manageable chronic disease with near-normal life expectancy when treatment is initiated promptly and maintained consistently. Recent antiretroviral therapy usually involves combination therapy at various stages throughout the HIV

Power System Technology
ISSN:1000-3673
Received: 16-07-2025 Revised: 05-08-2025 Accepted: 02-09-2025

pathogenesis to achieve optimal viral suppression with minimal development of resistance. The four main classes of drugs are: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) which interfere with the viral replication of DNA, non-nucleoside reverse transcriptase inhibitors (NNRTIs) which bind to reverse transcriptase enzyme, protease inhibitors (PIs) which block the processing of viral proteins, and integrase strand transfer inhibitors (INSTIs) which block the integration of viral DNA into the host chromosome (Steen et al., 2009).

Treatment initiation guidelines now recommend immediate antiretroviral therapy for all individuals diagnosed with HIV, regardless of CD4+ T-cell count or viral load, based on compelling evidence demonstrating clinical benefits and transmission prevention. The undetectable equals untransmittable (U=U) is a paradigm shift in HIV prevention, developed after years of rigorous clinical research showing that persons with undetectable viral loads due to regular adherence to ART cannot sexually transmit HIV to others. This scientific discovery has significant implications, regarding alleviating HIV-related stigma, enhancing the quality of life among individuals with HIV and supporting treatment as preventive measures (Addissouky et al., 2024). The success of treatment is assessed by performing a regular viral load test alongside a CD4+ T-cell count, with the aims of ensuring and sustaining a viral load to undetectable levels (thus, less than 50 copies/mL) and an immune system restoration. New ART regimens show high tolerability profiles and few side effects, good dosage schedules, and significant resistance development barriers, making it possible to achieve long-term viral suppression in an overwhelming majority of people who have access to therapy and can receive proper medical care.

Healthcare Worker Safety and Universal Precautions

The safety of healthcare workers in HIV care facilities depends on essential interventions through the use of comprehensive universal precaution measures, in which all patient specimens and materials are considered to be infectious, with or without known HIV status. Common precautions include hand washing procedures, the use of suitable personal protective equipment, safe injection procedures, handling and disposal of infected material, and environmental precautions. These guidelines acknowledge that many patients will be unaware of their HIV status and that the use of personal protective equipment offers the best possible protection against all bloodborne pathogens, such as HIV, hepatitis B, and hepatitis C, as well as against any splashes or aerosol-generating procedure, or against any random clothing contamination.

Proper handling of sharp objects is another key aspect of healthcare worker safety as percutaneous injuries are the leading occupational risk of HIV transmission. Prevention involves never recapping needles, use of safety-engineered tools where possible, placing sharp materials in proper containers immediately and hand-to-hand passages of sharp objects. Exposure management

Power System Technology
ISSN:1000-3673
Received: 16-07-2025 Revised: 05-08-2025 Accepted: 02-09-2025

procedures guaranty prompt management of possible occupational exposures with timely wound management, risk evaluation, baseline testing of source patient and exposed healthcare provider, and administration of post-exposure prophylaxis as necessary (Endashaw & Mekonnen, 2022). To establish HIV-safe healthcare settings, establishing a thorough staff education program, easy access to protective personal equipment, explicit exposure management guidelines, and organizational dedication towards ensuring that safety standards are maintained is necessary. The implementation of regular training updates, incident reporting systems, and continuous quality improvement efforts can ensure a high level of safety and minimize the risk of occupational transmission.

Drug Resistance and Treatment Monitoring

HIV drug resistance is a serious issue in long-term treatment management due to the high rate of HIV mutation, and the selective pressure of the antiretroviral drugs. Resistance is acquired when viral replication is maintained under the influence of sub-therapeutic drug levels and as a result, viral resistant variants are produced and may even predominate the viral population. The first mode of resistance is the transmission of resistant virus strains, and the second mode is resistance during treatment due to insufficient drug levels, poor compliance, or poor choice of regimen (McLean et al., 2024). Knowing resistance patterns assists in choosing and monitoring treatment based on the resistance profile and cross-resistance patterns of various classes of drugs, which have varied resistance patterns and cross-resistance patterns that affect therapy selection. Genotypic analysis of resistance testing determines the precise mutations linked to decreased drug susceptibility, which can be used to select the specific treatment according to the individual patterns of resistance.

Routine viral load measurements, usually performed 3-6 times per year in stable patients and more often in patients starting treatment or changing regimens, are required to identify treatment failure. Virologic failure, which is failure to gain or sustain viral control at levels below detectable levels, can be an indication of resistance to treatment, adherence issues, drug interactions, or pharmacological issues that influence drug levels. In case of treatment failure, thorough evaluation of resistance, adherence, review of drug interactions and pharmacokinetic considerations are done to minimize the impact of drug resistance. The change of regimens must be thoughtfully recalled in terms of drug resistance and treatment history, possible interactions with other drugs, and patient-specific considerations such as adherence issues, the effects of various drugs, and pill burdens preference. Adherence monitoring is an essential aspect of effective treatment, and different measures such as pill counting, pharmacy refills information, electronic monitors, and patient self-assessment can be used to shape and implement adherence barriers.

Power System Technology
ISSN:1000-3673
Received: 16-07-2025 Revised: 05-08-2025 Accepted: 02-09-2025

Psychosocial Aspects and Stigma Reduction

Stigma associated with HIV has proven to be one of the biggest obstacles to successful infection control, prevention, and treatment efforts across the globe. Examples of stigma include discrimination, social isolation, internalized shame, and institutional barriers that keep people out of testing, prevention services, and treatment. This stigma is based on historical links of HIV with marginalized groups of people, lack of knowledge on modes of transmission, fear of contracting the infection and moral prejudices on acts relating to HIV infection (Xu et al., 2021). Stigma response must involve multi-faceted strategies such as community education campaigns, training of healthcare providers, policy interventions safeguarding against discrimination, and community programs that confront and fight misconceptions and foster knowledge. Meaningful stigma reduction initiatives should include individual and systemic dimensions of reducing discrimination that enable individuals to obtain HIV services without fear of stigmatization or discrimination.

Mental health support is an important facet of full-scale HIV care and is aware of the intricate psychological issues related to HIV diagnosis, treatment, and management. Depression, anxiety, effects of trauma and symptoms of adjustment are common mental health issues that may greatly affect treatment compliance and quality of life. Disclosure is a continual problem as each individual balances personal freedom and autonomy with ethical judgment and legal considerations when deciding whether to disclose their HIV status to partners, family members, employers, and health practitioners. The complex relationships between psychological factors, social support, economic limitations, and side effects related to treatment that may demand specific interventions and continuous assistance can be considered a challenge in treatment adherence (Manickam et al., 2025). The development of supportive care settings includes educating medical professionals on culturally sensitive care, applying patient-centered care frameworks, offering peer support initiatives, and solving social factors influencing access to and outcomes of HIV care. HIV care has to cover not only the medical side of the infection but also the psychosocial environment, which determines individual health practices, adherence to treatment, and wellbeing of individuals with HIV/AIDS.

Conclusion

The comprehensive approach to HIV/AIDS infection control represents a remarkable evolution in medical science, public health practice, and social understanding of infectious disease management. Since its inception as an enigmatic and universally lethal disease, HIV has fundamentally changed the way we prevent infection, conduct diagnostic trials, address treatment regimes and how we treat patients. The diverse approaches to effective control of HIV infection discussed in this analysis indicate its complexity and interrelativity, as it needs to be jointly

Power System Technology
ISSN:1000-3673
Received: 16-07-2025 Revised: 05-08-2025 Accepted: 02-09-2025

addressed through clinical care, preventive actions in the population, research, and social support systems. Knowledge of the disease pathophysiology and progression has been the basis of specific interventions, whereas extensive knowledge of the transmission pathways has facilitated evidence-based prevention interventions that have led to a significant decrease in the number of new infections in numerous areas. The inventions of advanced quality diagnostic tools and groundbreaking therapeutic solutions such as the attainment of undetectable viral loads that do not transmit the infection is an unprecedented success in the management of infectious diseases. Employee safety measures in healthcare and monitoring drug resistance are the means to be able to sustainably and safely provide care and preserve the effectiveness of treatment over time. Most significantly, perhaps, the psychosocial part of HIV care and efforts to decrease stigma are critical elements of overall infection control that allow individuals to receive life-saving prevention and treatment services.

References

1. Addissouky, T. A., El Sayed, I. E. T., Ali, M. M., Alubiady, M. H. S., & Wang, Y. (2024). Bending the curve through innovations to overcome persistent obstacles in HIV prevention and treatment. *Journal of AIDS and HIV Treatment*, *6*(1), 44-53. https://www.scientificarchives.com/article/bending-the-curve-through-innovations-to-overcome-persistent-obstacles-in-hiv-prevention-and-treatment
2. Endashaw, E. E., & Mekonnen, T. T. (2022). Modeling the effect of vaccination and treatment on the transmission dynamics of hepatitis B virus and HIV/AIDS coinfection. *Journal of Applied Mathematics*, *2022*(1), 5246762. https://onlinelibrary.wiley.com/doi/full/10.1155/2022/5246762
3. Kaplan, J. E., Benson, C., Holmes, K. K., Brooks, J. T., Pau, A., Masur, H., ... & HIV Medicine Association of the Infectious Diseases Society of America. (2009). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. *MMWR Recomm Rep*, *58*(4), 1-207. https://www.cdc.gov/mmWR/preview/mmwrhtml/rr5804a1.htm
4. Landovitz, R. J., Scott, H., & Deeks, S. G. (2023). Prevention, treatment and cure of HIV infection. *Nature Reviews Microbiology*, *21*(10), 657-670. https://www.nature.com/articles/s41579-023-00914-1
5. Macchione, M. A., Aristizabal Bedoya, D., Figueroa, F. N., Muñoz-Fernández, M. Á., & Strumia, M. C. (2020). Nanosystems applied to HIV infection: prevention and

Power System Technology
ISSN:1000-3673
Received: 16-07-2025 Revised: 05-08-2025 Accepted: 02-09-2025

treatments. *International journal of molecular sciences*, *21*(22), 8647. https://www.mdpi.com/1422-0067/21/22/8647

6. Manickam, P., Varghese, T., En, L. L. X., Qin, K. Z., & Xin, K. H. (2025). Low attitude despite excellent knowledge in dental students on treating HIV/AIDS patients: Where are we lacking as educators?. *Journal of Education and Health Promotion*, *14*(1), 10. https://journals.lww.com/jehp/fulltext/2025/01310/low_attitude_despite_excellent_knowledge_in_dental.10.aspx
7. Masur, H., Brooks, J. T., Benson, C. A., Holmes, K. K., Pau, A. K., & Kaplan, J. E. (2014). Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. *Clinical infectious diseases*, *58*(9), 1308-1311. https://academic.oup.com/cid/article-abstract/58/9/1308/2895260
8. McLean, J. R., Zucker, J. E., Vail, R. M., Shah, S. S., Fine, S. M., McGowan, J. P., ... & Gonzalez, C. J. (2024). Prevention and Treatment of Mpox. https://www.ncbi.nlm.nih.gov/books/NBK603707/
9. Steen, R., Wi, T. E., Kamali, A., & Ndowa, F. (2009). Control of sexually transmitted infections and prevention of HIV transmission: mending a fractured paradigm. *Bulletin of the World Health Organization*, *87*, 858-865. https://www.scielosp.org/article/ssm/content/raw/?resource_ssm_path=/media/assets/bwho/v87n11/a15v8711.pdf
10. Workowski, K. A. (2015). Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. *Clinical Infectious Diseases*, *61*(suppl_8), S759-S762. https://academic.oup.com/cid/article/61/suppl_8/S759/345211
11. Xu, J. J., Han, M. J., Jiang, Y. J., Ding, H. B., Li, X., Han, X. X., ... & Shang, H. (2021). Prevention and control of HIV/AIDS in China: lessons from the past three decades. *Chinese medical journal*, *134*(23), 2799-2809. https://mednexus.org/doi/full/10.1097/CM9.0000000000001842